Holen Sie sich die Stockscreener-App
35.42
0.68%
0.24
Handel nachbörslich:
35.20
-0.22
-0.62%
Schlusskurs vom Vortag:
$35.18
Offen:
$35.54
24-Stunden-Volumen:
1.84M
Relative Volume:
0.50
Marktkapitalisierung:
$4.00B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-99.15M
KGV:
-38.09
EPS:
-0.93
Netto-Cashflow:
$-74.25M
1W Leistung:
-4.73%
1M Leistung:
+4.55%
6M Leistung:
+27.78%
1J Leistung:
-13.86%
1-Tages-Spanne:
$34.88
$36.17
1-Wochen-Bereich:
$34.67
$37.09
52-Wochen-Spanne:
$18.92
$43.55
Viking Therapeutics Inc Stock (VKTX) Company Profile
Firmenname
Viking Therapeutics Inc
Sektor
Branche
Telefon
858-704-4660
Adresse
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Vergleichen Sie VKTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
35.42 | 3.98B | 0 | -99.15M | -74.25M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-29 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-04-08 | Eingeleitet | Goldman | Neutral |
| 2025-02-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-02-07 | Eingeleitet | Citigroup | Neutral |
| 2024-12-02 | Eingeleitet | Piper Sandler | Overweight |
| 2024-11-22 | Eingeleitet | B. Riley Securities | Buy |
| 2024-11-04 | Bestätigt | H.C. Wainwright | Buy |
| 2024-09-11 | Eingeleitet | JP Morgan | Overweight |
| 2024-06-27 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-05-16 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-03-26 | Bestätigt | Oppenheimer | Outperform |
| 2024-03-07 | Eingeleitet | Jefferies | Buy |
| 2024-02-28 | Bestätigt | Oppenheimer | Outperform |
| 2023-05-31 | Fortgesetzt | ROTH MKM | Buy |
| 2023-03-28 | Bestätigt | Maxim Group | Buy |
| 2023-03-17 | Eingeleitet | Stifel | Buy |
| 2021-07-29 | Fortgesetzt | BTIG Research | Buy |
| 2021-05-25 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-05-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-05-01 | Eingeleitet | BTIG Research | Buy |
| 2019-07-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-25 | Eingeleitet | Stifel | Buy |
| 2019-03-29 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | Bestätigt | Maxim Group | Buy |
| 2019-02-22 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2018-12-12 | Eingeleitet | B. Riley FBR | Buy |
| 2018-11-19 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | Bestätigt | H.C. Wainwright | Buy |
| 2018-09-18 | Bestätigt | Maxim Group | Buy |
| 2018-09-18 | Bestätigt | Raymond James | Outperform |
| 2018-07-20 | Eingeleitet | SunTrust | Buy |
| 2018-06-28 | Eingeleitet | Raymond James | Outperform |
| 2018-06-01 | Bestätigt | Laidlaw | Buy |
| 2018-05-31 | Bestätigt | Maxim Group | Buy |
| 2018-03-26 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-11-28 | Bestätigt | Maxim Group | Buy |
| 2017-11-21 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Viking Therapeutics Inc Aktie (VKTX) Neueste Nachrichten
Viking Therapeutics: The Obesity Drugs Gold Rush Is Far From Over (NASDAQ:VKTX) - Seeking Alpha
Viking Therapeutics: A Tale of Clinical Momentum and Financial Strain - AD HOC NEWS
Here's How VKTX's Obesity Drug Is Moving Quickly Through Phase III - sharewise.com
Viking Therapeutics Accelerates Toward Pivotal Obesity Drug Data - AD HOC NEWS
Viking Therapeutics, Inc. $VKTX Shares Sold by Voya Investment Management LLC - MarketBeat
Viking Therapeutics Achieves Key Clinical Milestone Ahead of Schedule - AD HOC NEWS
Viking Therapeutics: A Wide-Open Oral GLP-1 Market (NASDAQ:VKTX) - Seeking Alpha
2 beaten-down stocks that could bounce back in 2026 - MSN
2 Beaten-Down Stocks That Could Bounce Back in 2026 - Finviz
The End of Shots? 5 Biotech Stocks Rethinking Diabetes - ADVFN
Viking Therapeutics: A High-Stakes Investment at a Critical Juncture - AD HOC NEWS
Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know - sharewise.com
Viking Therapeutics Shares Face Mounting Pressure - AD HOC NEWS
Insider Selling and Clinical Progress Shape Viking Therapeutics’ Stock Trajectory - AD HOC NEWS
Harbor Capital Advisors Inc. Trims Stock Holdings in Viking Therapeutics, Inc. $VKTX - MarketBeat
Viking Therapeutics: Investors Eye Pivotal Phase 3 Catalyst - AD HOC NEWS
Viking Therapeutics' Swing Trade Potential EmergesCompetition/Dilution Risks Remain (NASDAQ:VKTX) - Seeking Alpha
Price Action: Is Viking Therapeutics Inc. stock a good choice for value investorsMarket Volume Report & Real-Time Sentiment Analysis - moha.gov.vn
Viking Therapeutics, Inc. (VKTX) beats stock market upswing: What investors need to know - MSN
Market Moves: Is Viking Therapeutics Inc. stock a good choice for value investorsJuly 2025 Market Mood & Growth Focused Entry Reports - moha.gov.vn
Could Viking Therapeutics Become the Next Eli Lilly? - AOL.com
Why This Beaten-Down GLP-1 Stock Could Be a Steal - AOL.com
Here's How Much $100 Invested In Viking Therapeutics 5 Years Ago Would Be Worth Today - Sahm
Viking Therapeutics (VKTX) Is Up 8.9% After Rival Data Bolsters Its Oral Obesity Program - Yahoo Finance
Wall Street bulls look optimistic about Viking Therapeutics (VKTX): Should you buy? - MSN
Viking Therapeutics (VKTX): Revisiting Valuation After a Renewed Share Price Rally - simplywall.st
Viking Therapeutics, Inc. (VKTX) Beats Stock Market Upswing: What Investors Need to Know - sharewise.com
Wall Street Bulls Look Optimistic About Viking Therapeutics (VKTX): Should You Buy? - Finviz
(VKTX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Viking Bets Big On Next-Gen Obesity And Liver Drugs - Finimize
The Bull Case For Viking Therapeutics (VKTX) Could Change Following Fresh Validation Of Oral Obesity Drugs - simplywall.st
Viking Therapeutics, Inc. (NASDAQ:VKTX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
How to Buy Viking Therapeutics Stock (VKTX) - The Motley Fool
U.S. Capital Wealth Advisors LLC Buys 30,619 Shares of Viking Therapeutics, Inc. $VKTX - MarketBeat
Here is Why H.C. Wainwright Sees Immense Upside for Viking Therapeutics (VKTX) - Finviz
Here is why HC Wainwright sees immense upside for Viking Therapeutics (VKTX) - MSN
Profit Investment Management LLC Decreases Stock Position in Viking Therapeutics, Inc. $VKTX - MarketBeat
Viking Therapeutics, Inc. (VKTX) Rises Higher Than Market: Key Facts - MSN
Viking Therapeutics Stock Gains on Analyst Confidence and Pipeline Progress - AD HOC NEWS
Viking Therapeutics, Inc. (VKTX): A bull case theory - MSN
Published on: 2025-12-20 09:00:30 - ulpravda.ru
Analyst Confidence Fuels Viking Therapeutics Stock Rebound - AD HOC NEWS
Viking Therapeutics Inc. (VKTX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Viking Therapeutics: A Stock Poised Between High Conviction and High Short Interest - AD HOC NEWS
Chipmakers Recap: Is Viking Therapeutics Inc. stock a good choice for value investorsQuarterly Portfolio Report & Free Reliable Trade Execution Plans - Улправда
Viking Therapeutics Faces Intensifying Market Competition - AD HOC NEWS
Eli Lilly’s oral obesity drug passes maintenance test after Wegovy, Zepbound — Wall Street flags win for Viking Therapeutics - MSN
Analyst Confidence Soars for Viking Therapeutics with $102 Price Target - AD HOC NEWS
Why Viking Therapeutics Inc. stock remains undervaluedDividend Hike & Accurate Trade Setup Notifications - Улправда
Viking Therapeutics, Inc. (VKTX): A Bull Case Theory - Finviz
Eli Lilly’s Oral Obesity Drug Passes Maintenance Test After Wegovy, Zepbound — Wall Street Flags Win For Viking Therapeutics - Stocktwits
Finanzdaten der Viking Therapeutics Inc-Aktie (VKTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):